Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older.
- People who have been diagnosed with a specific type of brain tumour called Glioblastoma multiforme, located in the upper part of the brain, confirmed through tissue testing.
- People with a Karnofsky performance score above 60, which means a doctor has assessed that the person is able to carry out most daily activities with only some assistance needed (confirm with trial site).
- People who are suitable candidates for radiation therapy, as determined by their doctor.
- People who are able to understand and sign a consent form, or who have a legally authorised representative who can do this on their behalf.
Who may not be able to join:
- People who have another type of cancer, other than certain common skin cancers (non-melanoma skin cancers) or very early-stage cancers that have not spread (carcinoma in situ).
- People who had a chemotherapy wafer called a Gliadel wafer placed in the brain during surgery.
- People who are pregnant, as radiation therapy carries risks of harm to a developing baby.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kevin A Camphausen, M.D., National Cancer Institute (NCI)
Phone: (240) 858-3712
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To determine if an increase in urinary VEGF and MMP level, from the end of treatment to a patient's one-month follow-up examination following radiotherapy is predictive of one-year recurrence in patients with Glioblastoma multiforme
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.